Analysts’ Viewpoint on Animal Drug Compounding Market Scenario
Animal medicine compounding stakeholders have benefited significantly owing to rapid advancements in production techniques and growth in the pharmaceutical & biotechnology industry. People have become more conscious of the importance of improving animal health, which has increased the demand for veterinary medicine compounding. Officially approved drugs are not always available; hence, compounded medication is a better option for treating a wide range of illnesses. Chewable tablets, for example, are commercially approved products in specific dosage forms and are recommended for usage in specific animal species. The animal drug compounding market has matured due to the increase in owner approval of the practice in the past few years. Key players operating in the market are focusing on partnerships and collaborations to expand their global footprint.
Animal drug compounding is the method of combining, blending, or modifying ingredients to produce a medicine tailored to the needs of a single or small group of animals. These drugs can be used in veterinary medicine. These drugs are typically prepared by pharmacists or veterinarians. Compounded animal drug companies are working harder to maintain a steady supply of chemical compounds and materials to support veterinary compounding. Letco Medical, a provider of pharmaceutical ingredients, is now able to support a formula database that assists in choosing the ideal combination for any animal. Suppliers of APIs, bases, flavors, and formula for veterinary compounding collaborate closely with businesses that produce animal drugs.
Increase in number of people who own pets has led to the growth of the pharmacy practice of veterinary pharmacists who compound medications or assist pharmacists in producing compounded pet medications. Compounded medications are used to avoid allergens found in animals such as lactose, gluten, dyes, preservatives, and sugars. A veterinarian with knowledge of compounded medications could help in cases where discontinued medications are urgently needed. Governments of several countries are funding programs, fellowships, and grants to help pharmacists develop the necessary skills for medication compounding. For instance, Brazil has 7,211 compounding pharmacies and 16,000 compounding pharmacists.
The EAHP encourages health authorities in Europe to facilitate the transfer of drug store preparations among hospitals and invest in compounding services, as only healthcare facilities are able to respond to patients’ needs and extraordinary situations such as shortage of essential medicines. This is expected to create new opportunities in the market in the next few years.
The global companion animal population has increased in the past few years. The American Veterinary Medical Association (2017-2018 - U.S. Pet Ownership & Demographics Sourcebook) reported that 38.4% of households have dogs and 25.4% have cats. According to FEDIAF, 85 million households in the country own at least one pet animal, with pet-related services and products totaling EUR 19.7 Bn. Similarly, demand for companion animals is high in Brazil, India, China, and Singapore.
Rise in demand for exotic companion animals is driving the need for compounded medication in order to meet their personalized medical care needs. Animals cannot always be treated with the same medications as humans. Compounded medications are used for specific animals, as these can be tailored to the needs of each individual animal. Making medications more palatable by adding flavors and colors is a service that is especially beneficial for pets. Farmers and ranchers use medicines to ensure the health of their livestock, protect public health, and safeguard the food supply.
In terms of product, the anti-infectives segment is expected to grow at a rapid pace during the forecast period. Anti-infectives, which include antibacterial, antiviral, antifungal, and antiphrastic medications, work to prevent or treat infections. These drugs treat minor infections, and in most cases, cure serious infectious diseases such as pneumonia or tuberculosis. Routine procedures and complex surgeries pose a serious infection risk. Compounding allows to prescribe accurate doses when treating animal patients in need. This is anticipated to propel the anti-infectives segment during the forecast period.
Based on animal type, the companion animal segment dominated the global market in 2021. Dogs and cats are highly common companion animals. More than 60% of households have cats or dogs as companion animals. As per market trends, market players are striving to diversify their product portfolio through R&D, product launches, and other strategic initiatives. For instance, IDEXX Laboratories, a pet healthcare, veterinary diagnostics, and veterinary practice software company, provides a diverse range of tests, devices, and services for companion animal specialty drugs.
In terms of dosage form, the powders segment dominated the global market in 2021. Powders have better chemical stability than liquids and dissolve faster than tablets or capsules. This is a key factor driving the segment. Powder dosage forms have greater physicochemical stability and longer shelf life than liquid dosage forms. Oral powders containing water-soluble drugs dissolve faster than tablets or capsules, which require the disintegration of the tablet or capsule shell prior to dissolution.
Based on route of administration, the oral segment is projected to dominate the global market in 2021. The oral route of administration is commonly used for companion and food animals. Tablets, capsules, solutions, and suspensions are common oral medications for dogs and cats; pastes are also applied to cats' forelimbs, where they are licked and consumed.
North America accounted for around 40.0% share of the global market in 2021. Well-established healthcare infrastructure and rapid adoption of newer therapeutic strategies are expected to propel the market in the region in the near future. The U.S. is anticipated to account for major share of the market in North America due to presence of large chain pharmacies. The U.S. market is anticipated to be driven by technological advancements in highly efficient, precise, and automatic integrated compounding machines during the forecast period. Rise in cost of drugs and preference for customized drug preparation are expected to propel the market in North America in the near future.
The animal drug compounding market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Rise in acceptance of compounded veterinary planning and preparation is the key factor that is anticipated to increase the market size for animal drug compounding in the region. Moreover, surge in pet ownership is likely to drive the market size in Asia Pacific during the forecast period.
The global market is consolidated, with the presence of a small number of dominant players. Strategic alliances are being formed by key players in order to increase revenue and market share. Product line expansion and acquisitions & mergers are the other strategies used by players to expand their business footprint. Prominent players operating in the global animal drug compounding market are Custom Med Compounding Pharmacy, Triangle Compounding Pharmacy, Wellness Pharmacy of Cary, Wedgewood Pharmacy, Central Compounding Center South, Millers Pharmacy, Davis Islands Pharmacy, Smith's Pharmacy, Caringbah Compounding Pharmacy, Specialist Compounding Pharmacy Pte Ltd., and Tache Pharmacy.
Key players have been profiled in the market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 1.1 Bn |
|
Market Forecast Value in 2031 |
More than US$ 2.4 Bn |
|
Growth Rate (CAGR) for 2022-2031 |
7.4% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global animal drug compounding market was valued at US$ 1.1 Bn in 2021
The global animal drug compounding market is projected to reach more than US$ 2.4 Bn by 2031
The global animal drug compounding market is anticipated to grow at a CAGR of 7.4% from 2022 to 2031.
Increase in demand for companion animals and focus of manufacturers on drug dose adjustment & taste altering
The CNS agents product segment held more than 40.0% share of the global market in 2021
Wedgewood Pharmacy, Triangle Compounding Pharmacy, Davis Islands Pharmacy, Custom Med Compounding Pharmacy, Central Compounding Center South, Wellness Pharmacy of Cary, Caringbah Compounding Pharmacy, Millers Pharmacy, Smith's Pharmacy, Specialist Compounding Pharmacy Pte Ltd., and Tache Pharmacy
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Animal Drug Compounding Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Animal Drug Compounding Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Regulatory Scenario by Region/globally
5.3. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Animal Drug Compounding Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Anti-invectives
6.3.1.1. Metranidazole
6.3.1.2. Ketaconazole
6.3.1.3. Other Anti invectives
6.3.2. Anti-inflammatory
6.3.2.1. Prednisolone
6.3.2.2. Tramadol
6.3.2.3. Others
6.3.3. CNS Agents
6.3.3.1. Potassium bromide
6.3.3.2. Gabapentin
6.3.3.3. Other CNS agents
6.3.4. GI Drugs
6.3.4.1. Apomorphine
6.3.4.2. Ursodiol
6.3.4.3. Cisapride
6.3.4.4. Other GI Drugs
6.3.5. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Animal Drug Compounding Market Analysis and Forecast, by Animal Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Animal Type, 2017–2031
7.3.1. Companion Animal
7.3.1.1. Dogs
7.3.1.2. Cats
7.3.1.3. Others
7.3.2. Live Stock
7.4. Market Attractiveness Analysis, by Animal Type
8. Global Animal Drug Compounding Market Analysis and Forecast, by Dosage Form
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Dosage Form, 2017–2031
8.3.1. Capsules
8.3.2. Solutions
8.3.3. Powders
8.3.4. Suspension
8.3.5. Others
8.4. Market Attractiveness Analysis, by Dosage Form
9. Global Animal Drug Compounding Market Analysis and Forecast, by Route of Administration
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Route of Administration, 2017–2031
9.3.1. Oral
9.3.2. Injectable
9.3.3. Topical
9.3.4. Rectal
9.3.5. Ocular
9.4. Market Attractiveness Analysis, by Route of Administration
10. Global Animal Drug Compounding Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Animal Drug Compounding Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Anti-infectives
11.2.1.1. Metranidazole
11.2.1.2. Ketaconazole
11.2.1.3. Other Anti-infectives
11.2.2. Anti-inflammatory
11.2.2.1. Prednisolone
11.2.2.2. Tramadol
11.2.2.3. Others
11.2.3. CNS Agents
11.2.3.1. Potassium bromide
11.2.3.2. Gabapentin
11.2.3.3. Other CNS agents
11.2.4. GI Drugs
11.2.4.1. Apomorphine
11.2.4.2. Ursodiol
11.2.4.3. Cisapride
11.2.4.4. Other GI Drugs
11.2.5. Others
11.3. Market Value Forecast, by Animal Type, 2017–2031
11.3.1. Companion Animal
11.3.1.1. Dogs
11.3.1.2. Cats
11.3.1.3. Others
11.3.2. Live Stock
11.4. Market Value Forecast, by Dosage Form, 2017–2031
11.4.1. Capsules
11.4.2. Solutions
11.4.3. Powders
11.4.4. Suspension
11.4.5. Others
11.5. Market Value Forecast, by Route of Administration, 2017–2031
11.5.1. Oral
11.5.2. Injectable
11.5.3. Topical
11.5.4. Rectal
11.5.5. Ocular
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Animal Type
11.7.3. By Dosage Form
11.7.4. By Route of Administration
11.7.5. By Country
12. Europe Animal Drug Compounding Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Anti-infectives
12.2.1.1. Metranidazole
12.2.1.2. Ketaconazole
12.2.1.3. Other Anti-infectives
12.2.2. Anti-inflammatory
12.2.2.1. Prednisolone
12.2.2.2. Tramadol
12.2.2.3. Others
12.2.3. CNS Agents
12.2.3.1. Potassium bromide
12.2.3.2. Gabapentin
12.2.3.3. Other CNS agents
12.2.4. GI Drugs
12.2.4.1. Apomorphine
12.2.4.2. Ursodiol
12.2.4.3. Cisapride
12.2.4.4. Other GI Drugs
12.2.5. Others
12.3. Market Value Forecast, by Animal Type, 2017–2031
12.3.1. Companion Animal
12.3.1.1. Dogs
12.3.1.2. Cats
12.3.1.3. Others
12.3.2. Live Stock
12.4. Market Value Forecast, by Dosage Form, 2017–2031
12.4.1. Capsules
12.4.2. Solutions
12.4.3. Powders
12.4.4. Suspension
12.4.5. Others
12.5. Market Value Forecast, by Route of Administration, 2017–2031
12.5.1. Oral
12.5.2. Injectable
12.5.3. Topical
12.5.4. Rectal
12.5.5. Ocular
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Animal Type
12.7.3. By Dosage Form
12.7.4. By Route of Administration
12.7.5. By Country/Sub-region
13. Asia Pacific Animal Drug Compounding Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Anti-infectives
13.2.1.1. Metranidazole
13.2.1.2. Ketaconazole
13.2.1.3. Other Anti-infectives
13.2.2. Anti-inflammatory
13.2.2.1. Prednisolone
13.2.2.2. Tramadol
13.2.2.3. Others
13.2.3. CNS Agents
13.2.3.1. Potassium bromide
13.2.3.2. Gabapentin
13.2.3.3. Other CNS agents
13.2.4. GI Drugs
13.2.4.1. Apomorphine
13.2.4.2. Ursodiol
13.2.4.3. Cisapride
13.2.4.4. Other GI Drugs
13.2.5. Others
13.3. Market Value Forecast, by Animal Type, 2017–2031
13.3.1. Companion Animal
13.3.1.1. Dogs
13.3.1.2. Cats
13.3.1.3. Others
13.3.2. Live Stock
13.4. Market Value Forecast, by Dosage Form, 2017–2031
13.4.1. Capsules
13.4.2. Solutions
13.4.3. Powders
13.4.4. Suspension
13.4.5. Others
13.5. Market Value Forecast, by Route of Administration, 2017–2031
13.5.1. Oral
13.5.2. Injectable
13.5.3. Topical
13.5.4. Rectal
13.5.5. Ocular
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Animal Type
13.7.3. By Dosage Form
13.7.4. By Route of Administration
13.7.5. By Country/Sub-region
14. Latin America Animal Drug Compounding Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Anti-infectives
14.2.1.1. Metranidazole
14.2.1.2. Ketaconazole
14.2.1.3. Other Anti-infectives
14.2.2. Anti-inflammatory
14.2.2.1. Prednisolone
14.2.2.2. Tramadol
14.2.2.3. Other Anti-inflammatory
14.2.3. CNS Agents
14.2.3.1. Potassium bromide
14.2.3.2. Gabapentin
14.2.3.3. Other CNS agents
14.2.4. GI Drugs
14.2.4.1. Apomorphine
14.2.4.2. Ursodiol
14.2.4.3. Cisapride
14.2.4.4. Other GI Drugs
14.2.5. Others
14.3. Market Value Forecast, by Animal Type, 2017–2031
14.3.1. Companion Animal
14.3.1.1. Dogs
14.3.1.2. Cats
14.3.1.3. Others
14.3.2. Live Stock
14.4. Market Value Forecast, by Dosage Form, 2017–2031
14.4.1. Capsules
14.4.2. Solutions
14.4.3. Powders
14.4.4. Suspension
14.4.5. Others
14.5. Market Value Forecast, by Route of Administration, 2017–2031
14.5.1. Oral
14.5.2. Injectable
14.5.3. Topical
14.5.4. Rectal
14.5.5. Ocular
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Animal Type
14.7.3. By Dosage Form
14.7.4. By Route of Administration
14.7.5. By Country/Sub-region
15. Middle East & Africa Animal Drug Compounding Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Anti-infectives
15.2.1.1. Metranidazole
15.2.1.2. Ketaconazole
15.2.1.3. Other Anti-infectives
15.2.2. Anti-inflammatory
15.2.2.1. Prednisolone
15.2.2.2. Tramadol
15.2.2.3. Other Anti-inflammatory
15.2.3. CNS Agents
15.2.3.1. Potassium bromide
15.2.3.2. Gabapentin
15.2.3.3. Other CNS agents
15.2.4. GI Drugs
15.2.4.1. Apomorphine
15.2.4.2. Ursodiol
15.2.4.3. Cisapride
15.2.4.4. Other GI Drugs
15.2.5. Others
15.3. Market Value Forecast, by Animal Type, 2017–2031
15.3.1. Companion Animal
15.3.1.1. Dogs
15.3.1.2. Cats
15.3.1.3. Others
15.3.2. Live Stock
15.4. Market Value Forecast, by Dosage Form, 2017–2031
15.4.1. Capsules
15.4.2. Solutions
15.4.3. Powders
15.4.4. Suspension
15.4.5. Others
15.5. Market Value Forecast, by Route of Administration, 2017–2031
15.5.1. Oral
15.5.2. Injectable
15.5.3. Topical
15.5.4. Rectal
15.5.5. Ocular
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Country
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Animal Type
15.7.3. By Dosage Form
15.7.4. By Route of Administration
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Wedgewood Pharmacy
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. Triangle Compounding Pharmacy
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. Davis Islands Pharmacy
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Custom Med Compounding Pharmacy
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Central Compounding Center South
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Wellness Pharmacy of Cary
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Caringbah Compounding Pharmacy
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Millers Pharmacy
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. Smith's Pharmacy
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Company Financials
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. Specialist Compounding Pharmacy Pte Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Company Financials
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Tache Pharmacy
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Company Financials
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis
List of Tables
Table 01: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031
Table 03: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031
Table 04: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031
Table 05: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031
Table 06: Global Animal Drug Compounding Market Value (US$ My) Forecast, by Others, 2017–2031
Table 07: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 08: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031
Table 09: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 10: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 11: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 12: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 13: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 14: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031
Table 15: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031
Table 16: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031
Table 17: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031
Table 18: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031
Table 19: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 20: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031
Table 21: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 22: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 23: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 24: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 25: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031
Table 26: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031
Table 27: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031
Table 28: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031
Table 29: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031
Table 30: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 31: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031
Table 32: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 33: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 34: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 35: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 36: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031
Table 37: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031
Table 38: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031
Table 39: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031
Table 40: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031
Table 41: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 42: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031
Table 43: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 44: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 45: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 46: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 47: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031
Table 48: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031
Table 49: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031
Table 50: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031
Table 51: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031
Table 52: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 53: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031
Table 54: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 55: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 56: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 57: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 58: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031
Table 59: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031
Table 60: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031
Table 61: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031
Table 62: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031
Table 63: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031
Table 64: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031
Table 65: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 66: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
List of Figures
Figure 01: Global Animal Drug Compounding Market, by Product, 2021 and 2031
Figure 02: Global Animal Drug Compounding Market Attractiveness Analysis, Product, 2022–2031
Figure 03: Global Animal Drug Compounding Market (US$ Mn), by Anti-infectives, 2017–2031
Figure 04: Global Animal Drug Compounding Market (US$ Mn), by Anti-inflammatory, 2017–2031
Figure 05: Global Animal Drug Compounding Market (US$ Mn), by CNS Agents, 2017–2031
Figure 06: Global Animal Drug Compounding Market (US$ Mn), by GI Drugs, 2017–2031
Figure 07: Global Animal Drug Compounding Market (US$ Mn), by Others, 2017–2031
Figure 08: Global Animal Drug Compounding Market, by Animal Type, 2021 and 2031
Figure 09: Global Animal Drug Compounding Market Attractiveness Analysis, Animal Type, 2022–2031
Figure 10: Global Animal Drug Compounding Market (US$ Mn), by Companion Animal, 2017–2031
Figure 11: Global Animal Drug Compounding Market (US$ Mn), by Livestock Animal, 2017–2031
Figure 12: Global Animal Drug Compounding Market, by Dosage Form, 2021 and 2031
Figure 13: Global Animal Drug Compounding Market Attractiveness Analysis, Dosage Form, 2022–2031
Figure 14: Global Animal Drug Compounding Market (US$ Mn), by Capsules, 2017–2031
Figure 15: Global Animal Drug Compounding Market (US$ Mn), by Solutions, 2017–2031
Figure 16: Global Animal Drug Compounding Market (US$ Mn), by Powders, 2017–2031
Figure 17: Global Animal Drug Compounding Market (US$ Mn), by Suspension, 2017–2031
Figure 18: Global Animal Drug Compounding Market (US$ Mn), by Others, 2017–2031
Figure 19: Global Animal Drug Compounding Market, by Route of Administration, 2021 and 2031
Figure 20: Global Animal Drug Compounding Market Attractiveness Analysis, Route of Administration, 2022–2031
Figure 21: Global Animal Drug Compounding Market (US$ Mn), by Oral, 2017–2031
Figure 22: Global Animal Drug Compounding Market (US$ Mn), by Injectable, 2017–2031
Figure 23: Global Animal Drug Compounding Market (US$ Mn), by Topical, 2017–2031
Figure 24: Global Animal Drug Compounding Market (US$ Mn), by Rectal, 2017–2031
Figure 25: Global Animal Drug Compounding Market (US$ Mn), by Ocular, 2017–2031
Figure 26: Global Animal Drug Compounding Market Value Share Analysis, by Region, 2021 and 2031
Figure 27: Global Animal Drug Compounding Market Attractiveness Analysis, by Region, 2022–2031
Figure 28: North America Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 29: North America Animal Drug Compounding Market Value Share Analysis, by Country, 2021 and 2031
Figure 30: North America Animal Drug Compounding Market Attractiveness Analysis, by Country, 2022–2031
Figure 31: North America Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031
Figure 32: North America Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031
Figure 33: North America Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031
Figure 34: North America Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031
Figure 35: North America Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031
Figure 36: North America Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 37: North America Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 38: North America Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 39: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 40: Europe Animal Drug Compounding Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 41: Europe Animal Drug Compounding Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 42: Europe Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031
Figure 43: Europe Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031
Figure 44: Europe Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031
Figure 45: Europe Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031
Figure 46: Europe Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031
Figure 47: Europe Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 48: Europe Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 49: Europe Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 50: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 51: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 52: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 53: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031
Figure 54: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031
Figure 55: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031
Figure 56: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031
Figure 57: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031
Figure 58: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 59: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 60: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 61: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 62: Latin America Animal Drug Compounding Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 63: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 64: Latin America Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031
Figure 65: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031
Figure 66: Latin America Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031
Figure 67: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031
Figure 68: Latin America Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031
Figure 69: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 70: Latin America Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 71: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 72: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 73: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 74: Middle East and Africa Animal Drug Compounding Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 75: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031
Figure 76: Middle East & Africa Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031
Figure 77: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031
Figure 78: Middle East & Africa Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031
Figure 79: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031
Figure 80: Middle East & Africa Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031
Figure 81: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 82: Middle East & Africa Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Animal Drug Compounding Market
